Table 2.
Intragroup analysis of different outcome measures between baseline and week 12.
| Measure | Olanzapine Baseline |
Olanzapine Week 12 |
T | P | 95% CI | Risperidone Baseline |
Risperidone Week 12 |
T | P | 95% CI |
|---|---|---|---|---|---|---|---|---|---|---|
| SAPS | 63.61 ± 3.86 | 54.96 ± 3.42 | 9.187 | 0.0001 | 6.77, 10.53 | 62.19 ± 4.11 | 56.31 ± 3.02 | 6.315 | 0.0001 | 4.02, 7.74 |
| SANS | 46.26 ± 3.37 | 42.74 ± 3.69 | 3.858 | 0.0003 | 1.69, 5.35 | 46.83 ± 3.75 | 45.28 ± 3.06 | 1.754 | 0.08 | −0.22, 3.32 |
| CGI-S | 3.65 ± 1.16 | 3.10 ± 1.03 | 1.942 | 0.05 | −0.02, 1.12 | 3.25 ± 0.12 | 3.17 ± 0.16 | 2.191 | 0.03 | 0.01, 0.15 |
| SAI | 3.49 ± 0.61 | 3.83 ± 0.11 | −3.004 | 0.003 | −0.57, −0.11 | 3.51 ± 1.03 | 3.97 ± 0.74 | −1.987 | 0.05 | −0.92, 0.00 |
| SAS | 0.35 ± 0.76 | 0.38 ± 0.02 | −0.216 | 0.82 | −0.31, 0.25 | 0.36 ± 0.11 | 0.45 ± 0.19 | −2.245 | 0.02 | −0.17, −0.01 |
SAPS: Scale for Assessment of Positive Symptoms; SANS: Scale for Assessment of Negative Symptoms; CGI-S: Clinical Global Impressions-Severity Scale; SAI: Schedule for Assessment of Insight; and SAS: Simpson Angus Scale.